We herein report a case of a 37-year-old Brazilian man born in Minas Gerais, an endemic area of leishmaniasis in Brazil, who was receiving treatment with infliximab from 2005 to 2015 and since 2015 has been in use of adalimumab 40 mg every 2 weeks for ankylosing spondylitis. He presented to the otolaryngologist outpatient clinic of the University of São Paulo Medical School Hospital complaining of rhinorrhea and nasal obstruction for the last 3 months. Nasopharyngolaryngoscopy revealed a nasal granulomatous lesion with crust formation. The lesion was biopsied and initial hypotheses were leishmaniasis, lymphoma, syphilis, and Wegener granulomatosis. Antineutrophil cytoplasmic antibodies (ANCA) were negative. Serological assays for leishmaniasis were positive: ELISA with titers above 1:1280 and indirect immunofluorescence with a titer of 1:80. Hematoxylin and eosin staining showed a chronic lymphoplasmocytic infiltrate with ulcerated areas in the nasal mucosa (Fig 1) . Amastigote forms were not visualized by optic microscopy. Polymerase chain reaction (PCR) was positive for Leishmania in the biopsy tissue [1] . Surprisingly, immunohistochemistry of the biopsy revealed CD3-positive, CD20-negative, CD56-negative, CD30-negative, Cyclin D1-negative, Ki-67-positive (high levels), CD4-positive (focal), CD8-positive (focal), CD7-positive, TIA-1-positive, and Granzyme B-positive cells, suggesting natural killer (NK)/T-cell lymphoma (Fig 2) . The patient underwent a positron emission tomography (PET)/computed tomography (CT) scan, which was negative. CT scans of the sinus, chest, and abdomen were normal. In spite of the immunohistochemistry results, he was treated with a liposomal amphotericin B cumulative dose of 35 mg/kg [2], with complete remission of the lesions after 3 months.
Discussion
The highlights of this article are the possibility of the reactivation of latent infections in patients receiving treatment with monoclonal antibodies for inflammatory and/or chronic autoimmune disease [3] and the need to consider these infections in the clinical and laboratorial differential diagnosis of tissue lesions in order to avoid misdiagnosis and wrong treatments.
Cutaneous and mucosal leishmaniasis usually induce a predominant type 1 immune response, characterized by high levels of interferon gamma (IFN-ɣ) and tumor necrosis factor alpha (TNF-α) [4] . Although associated with the control of infection, Th1 immune response can cause tissue damage if not modulated [5] . The parasite can persist in scars of old lesions for years, sustained by a persistent, well-modulated Th1 local immune response, even after treatment.
In mucosal leishmaniasis, TNF-α levels in the tissue are high before treatment and decrease after therapy [6] . The reactivation of latent infection is related to the deregulation of specific immune responses, decreasing inflammatory cytokines such as INF-and TNF-α associated with increasing Th2 cytokines interleukin 4 (IL4) and interleukin 10 (IL10) [7] .
Conclusion
Mucosal leishmaniasis should be part of the differential diagnosis of nasal lesions in patients on an immunosuppressive regimen, particularly those on anti-TNFα drugs [3, 8] . Diagnosis can be challenging, and the T-cell-mediated response induced by the parasite can render immunohistochemical analysis difficult, leading to misdiagnosis with nasal lymphoma.
Could the chronic inflammation triggered by mucosal leishmaniasis induce the development of lymphoma as can occur in the case of Helicobacter pylori infection and the development of mucosa-associated lymphatic tissue (MALT) lymphoma of the gastrointestinal tract [9, 10, 11] ? We believe that the treatment of nasal leishmaniasis may be sufficient to improve local lymphoproliferation and to heal the lesion.
The negative CT and PET-CT scans, the positive PCR for Leishmania, and the healing of lesions after the 2 treatments reinforce and corroborate our hypothesis of mucosal leishmaniasis.
Once again, we emphasize the necessity of including latent infections in the investigation and differential diagnosis of lesions in patients on treatment with anti-TNFα drugs, mainly in those who live in or travel to endemic areas.
